Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serine/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer.

Biochemical pharmacology - 1 Jul 2024

Zhu Zhenyun, Xiang Qin, Li Shuangqiong, Chen Chen, Shi Jian

Abstract excerpt

Although Janus kinase 2 (JAK2) plays a critical role in the progression of triple-negative breast cancer (TNBC), its inhibitors are incapable of eradicating these tumor cells, implicating drug resistance mechanisms exist. Our evidences show that TNBC cells express high level of Serine/Threonine Kinase 16 (STK16) when JAK2 signaling is blocked. Pharmacological inhibition or silencing of STK16 significantly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Phosphorylation

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Share to STAT3 Transcription Factor

Share to Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 38723720
DOI: 10.1016/j.bcp.2024.116268

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serine/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer.PMID 38723720Read ↗

Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancerSemantic proximity Read ↗

Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axisSemantic proximity Read ↗

JAK2 regulates paclitaxel resistance in triple negative breast cancersSemantic proximity Read ↗

Noncanonical pS727 post translational modification dictates major STAT3 activation and downstream functions in breast cancer.Semantic proximity Read ↗

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.Semantic proximity Read ↗

Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast CancerSemantic proximity Read ↗

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistanceSemantic proximity Read ↗

A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cellsSemantic proximity Read ↗

The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.Semantic proximity Read ↗

TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional activity.Semantic proximity Read ↗

Stat3 Tyrosine 705 and Serine 727 Phosphorylation Associate With Clinicopathological Characteristics and Distinct Tumor Cell Phenotypes in Triple-Negative Breast Cancer.Semantic proximity Read ↗

Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.